Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lite Strategy, Inc.LITS · Entity 7396 | Director | November 14, 2025 | November 19, 2025 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Director · CEO and President | February 25, 2020 | February 27, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lite Strategy, Inc.
Report date November 14, 2025 · Filed November 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-11-14 | Direct | 55,000 |
Reported balance
After 2025-11-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-14 · Grant · Acquired 55,000 · Balance 55,000 F2: Received as compensation for service on the Board. F1: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026.
F2: Received as compensation for service on the Board.
Sierra Oncology, Inc.
Report date February 25, 2020 · Filed February 27, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.31 · Expires 2030-02-25 | Direct | 359,158 |
Reported balance
After 2020-02-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-25 · Grant · Acquired 359,158 · Balance 359,158 F1: The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2025 Filed Nov 19, 2025 18:41 UTC | Lite Strategy, Inc. LITS · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $2.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-287655 · ownership.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-11-14 F2 · price: Received as compensation for service on the Board. F1 · derivative.exercise_date: Customary annual grant to non-employee directors of options to purchase shares of common stock. Such options shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning December 14, 2025 and continuing on the first day of each calendar month following such date and continuing through November 14, 2026. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 01:38 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0000929638-25-002637 · form4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-07-15 F1 · security: Customary annual grant to non-employee directors of options to purchase shares of common stock was not made during the fiscal year ended June 30, 2025. Read SEC document |
| September 29, 2023 Filed Oct 12, 2023 23:41 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0000929638-23-002772 · form4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-09-29 F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 20:27 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000899243-22-025711 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-07-05 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:59 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-045658 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 17:30 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-20-018617 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-07-02 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 16:14 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 359,158 | $0.00 Strike: $13.31 | $0.00 |
DisclosureSEC source: 0001209191-20-013404 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,158 Underlying: Common Stock · 359,158 shares Expires 2030-02-25 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:32 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-19-040979 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 17:26 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 607,500 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001209191-19-016737 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 607,500 Underlying: Common Stock · 607,500 shares Expires 2029-03-04 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:27 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001209191-18-042670 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-07-12 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 17:53 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 562,780 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-18-017777 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,780 Underlying: Common Stock · 562,780 shares Expires 2028-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 18:33 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantOption to purchase shares of common stock · Derivative | 40,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001209191-17-044529 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,793 Underlying: Common Stock par value $0.00000002 · 40,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 17:33 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001209191-17-019350 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2027-03-06 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:08 UTC | Sierra Oncology, Inc. DNAI · Entity 125698 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001209191-16-144426 · doc4.xml · derivative · entry 1 Glover Nicholas · CIK 0001578888 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2026-09-30 F1 · derivative.exercise_date: The option vests as to 2.7778% of the total shares monthly, beginning on October 30, 2016, with 100% of the total shares vested and exercisable on September 30, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.